Project Grant R01CA299969
Award Date
5/16/25
Completion Date
4/30/30
Dollars Obligated
$745K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $231,413.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to establish in vitro models that recapitulate the carcinogenic process of human germ cell neoplasia in situ (GCNIS), which are precursor lesions to testicular germ cell tumors. The project aims to generate induced pluripotent stem cell-derived primordial germ cell-like cells and genetically...
This $176,238 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of a novel model to study the effects of LINE-1 retrotransposons on disease and normal physiology. The project aims to establish a reliable knockdown model using functionalized nanobodies to eliminate LINE-1 proteins, which are hypothesized to play a role in various diseases. The research will involve...
This federal Project Grant award, titled "Genome-Wide Approaches to Non-Invasive Screening and Characterization of Ovarian Cancers," was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $107,948 award will support research to develop a high-performance, accessible liquid biopsy screening test for early detection of ovarian cancer. The key objectives are to: 1) Expand bioinformatics methods to study repeat elements in...
This $2,073,138 Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), is focused on discovering a new class of tumor antigens and T-cell receptors (TCRs) targeting platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The primary awardee, the University of California, Los Angeles (UCLA), will leverage long-read RNA sequencing, immunopeptidomics, and computational epitope prediction to identify cancer-specific peptide...
This $635,033 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University supports research to advance understanding of the genetic basis of a recently recognized cancer-prone syndrome caused by long telomere length. The project aims to identify additional novel mechanisms for this "long telomere syndrome", with the goal of identifying high-risk groups who could benefit from early screening and...
This $485,558 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to characterize a novel glutathione-related metabolic pathway that drives metastatic outgrowth in pancreatic ductal adenocarcinoma (PDA). The key objectives are to molecularly characterize two pathway factors, GSTT1 and SLC38A4, that are specifically expressed...
This federal Project Grant award of $131,600.00 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the President and Fellows of Harvard College to understand and exploit apoptotic dysregulation in ovarian cancer. The research aims to ascertain apoptotic regulation and pro-survival protein dependence in pre-malignant and malignant stages of ovarian cancer transformation, assess the efficacy of combining pro-survival protein targeting drugs...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This $631,156 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover core mechanisms facilitating lineage plasticity (LP) in EGFR-mutant lung cancer. The primary objectives are to systematically assess the epigenetic, transcriptional, and signaling changes underlying the transformation from lung adenocarcinoma (LUAD) to the more aggressive small cell lung cancer (SCLC) phenotype. The...
The federal Project Grant award R03CA286532 for $151,000.00 was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award supports research to identify essential biomarkers and genes involved in the formation and behavior of polyploid cancer cells, with a focus on high-grade serous ovarian carcinoma (HGSOC). The key products and services to be delivered include: 1) conducting a CRISPR-Cas9 genetic screen to determine genes...